BMY (NYSE) - Bristol-Myers Squibb Company

Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US1101221083
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BMY (NYSE) - Bristol-Myers Squibb Company
Market Cap. 137,543m USD
Enterprise Value 166,549m USD (+21%)
GiC Sector Health Care
GiC Group Pharmaceuticals, Biotechnology & Life Sciences
GiC Industry Pharmaceuticals
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1972-01-01


Fundamental 5.00
Dividend 6.13
Technical 3.46
Performance -4.00
Analysts 3.76
Price / Fair Price TR 1.10
Price / Fair Price DCF todo


Growth TTM -15.07%
CAGR 5y 7.46%
CAGR / Mean Drawdown 5y 0.76
Sharpe Ratio TTM -0.99
Alpha vs SP500 TTM -18.66
Beta vs SP500 5y weekly 0.67
Volatility GJR Garch 1y 22.88%
CAPM 8.25%
Correlation TTM -0.33
Max Drawdown 5y 31%
Mean Drawdown 5y 9.8%
Price / SMA 200 days 11.06%
Current Volume 8203.1k
Average Volume 8036.4k


Rate TTM 2.33
Yield TTM 3.65%
Div. CAGR 5y -1.12%
Consistency of Dividends all time 94.2%